An observation with therapeutic potential arose from comparing structures of MLi-2 bound to the C-terminal half of LRRK2 in either its wild-type form or carrying G2019S, the most common PD-linked mutation (Fig. 5, E and F) (50). This evidence concerns the gene LRRK2 and Parkinson disease.